

b. the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:24-27; and wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:28-31.

[0019b] In another embodiment, the invention is a process for preparing an isolated antibody as disclosed herein, comprising preparing said antibody from a host cell that secretes said antibody.

[0019c] In another embodiment, the invention is the use of an effective amount of the antibody as disclosed herein in the manufacture of a medicament for treating or preventing a condition in a patient in need of treatment or prevention.

[0019d] In another embodiment, the invention is an antibody as disclosed herein for use as a medicament.

[0019e] In another embodiment, the invention is the use of an effective amount of the antibody as disclosed herein in the manufacture of a medicament for treating or preventing a condition in a patient in need of treatment or prevention, wherein the condition is an ocular disease.

BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 depicts the binding analysis of an anti-Factor Bb monoclonal antibody, using

[0021] Figure 2 shows the results of a hemolysis assay using either anti-Factor B or anti-Factor Bb antibodies in the presence of 10% normal human serum.

14. The pharmaceutical composition of claim 13, further comprising an additional active agent.
15. The antibody of claim 1 for use as a medicament.
16. Use of an effective amount of the antibody of claim 1 in the manufacture of a medicament for treating or preventing a condition in a patient in need of treatment or prevention, wherein the condition is an ocular disease.
17. The use of claim 16, wherein the condition is age-related macular degeneration (AMD).
18. The antibody of claim 1, wherein the antibody comprises a light chain variable domain amino acid sequence of SEQ ID NO:25 and a heavy chain variable domain amino acid sequence of SEQ ID NO:30.